search
Back to results

MEMENTO-VAScular COmponents of Dementia (VASCOD)

Primary Purpose

Alzheimer's Disease (AD), Alzheimer's Disease (AD) Related Disorders

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
in Memento-VASCOD
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Alzheimer's Disease (AD) focused on measuring Alzheimer's disease, Mild Cognitive Impairment

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants to MEMENTO-Vascod should be included in MEMENTO.
  • To have signed a specific MEMENTO-Vascod informed consent form, prior to any Vascod ancillary study related procedures
  • To be aged 50 years old and above
  • To have a Clinical Dementia Rating scale <0.5 and to be not demented;

Exclusion Criteria:

  • Are under guardianship
  • Live in skilled nursing facility
  • Are Pregnant or breast feeding women
  • Meet brain MRI exclusion criteria (Same criteria as in Memento main protocol)

Sites / Locations

  • CHU d'Amiens
  • CHU de Bordeaux - Pellegrin
  • CHU de Dijon
  • CHU de Lille
  • Hospices civils de Lyon
  • AP-HM
  • CHU de Montpellier
  • AP-HP - Hôpital BROCA
  • AP-HP - Hôpital LARIBOISIERE
  • CHU de Strasbourg

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Alzheimer's disease and related disorders

Arm Description

Outcomes

Primary Outcome Measures

Change in cognitive performances over

Secondary Outcome Measures

Progression to clinical dementia of Alzheimer's type according to standardized criteria
standardized criteria : Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and National Institute of Neurological and Communicative Disorders and Stroke Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) classifications
Change in CSF and blood amyloid biomarkers of AD
Change in brain atrophy and hippocampal volumes
Progression of small vessels disease markers (white matter lesions, lacunar infarcts, microbleeds)

Full Information

First Posted
October 1, 2014
Last Updated
January 27, 2022
Sponsor
University Hospital, Bordeaux
Collaborators
Ministry for Health and Solidarity, France
search

1. Study Identification

Unique Protocol Identification Number
NCT02264899
Brief Title
MEMENTO-VAScular COmponents of Dementia
Acronym
VASCOD
Official Title
MEMENTO-VAScular COmponents of Dementia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
November 4, 2014 (Actual)
Primary Completion Date
October 29, 2021 (Actual)
Study Completion Date
October 29, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Ministry for Health and Solidarity, France

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A Multicenter national longitudinal cohort study including at least 800 individuals recruited from French Research Memory Centers and followed up over 36 months and included in Memento.
Detailed Description
Alzheimer's disease (AD) is a neurodegenerative disorder thought to be caused by the accumulation of the peptide amyloid beta and the hyperphosphorylated tau protein in the brain. There are increasing arguments in favor of an important role of vascular damages in the development and progression of AD. The time course of these vascular alterations and how they relate to dementia and AD pathology remain unclear, as no protocol that allows the development of the diverse vascular pathology to be scored, and hence to be tracked with ageing, has so far been developed and widely validated. The aims of this project are to investigate, in a large clinical sample of patients presenting either isolated cognitive complaints or light to mild cognitive deficits, how vascular risk factors and vascular alterations (assessed at macro and micro levels) relate to cerebrovascular disease and cognitive decline. The primary objective of this ancillary study is to investigate the prospective association between vascular risk factors, inflammation markers and vascular damages on cognitive decline and neurodegeneration progression over up to 4 years of follow-up in a sample of individuals presenting with a spectrum of cognitive profiles ranging from isolated cognitive complaints to cognitive deficits without dementia. The secondary objectives are the following To investigate the role of vascular risk factors (diabetes, hypertension, hypercholesterolemia) and vascular damages on progression to clinical dementia over up to 4-year follow-up. To study whether the interaction between changes in markers of macrovascular and microvascular structures on cognitive deficits progression. To study the association between in BP, hypertension, antihypertensive treatments and vascular damages, progression of cerebrovascular disease seen at MRI and cognitive decline and dementia risk To assess the temporality of vascular damages burden on neurodegeneration To assess the association between retinal vasculature defect and brain neurovascular damages To study the link between vascular damages and AD pathology (Cerebro-Spinal Fluid (CSF) and Positron emission tomography (TEP) amyloid imaging) biomarkers in the subsample of participants having all measures available To investigate how inflammatory markers mediate the association between vascular damages and neurodegeneration To assess whether vascular factors and neurodegenerative factors act independently or synergistically on the course of cognitive decline To assess simultaneously the impact of vascular damages on end organs (brain, eye, and kidney) To study the correlation between cerebral blood flow, measured by Arterial spin-Labeled (ASL) MRI and cognitive decline To study whether genetic polymorphisms revealed from genome-wide association studies (GWAS) of AD of vascular factors could modulate the association between vascular damages and cognitive decline

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer's Disease (AD), Alzheimer's Disease (AD) Related Disorders
Keywords
Alzheimer's disease, Mild Cognitive Impairment

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
332 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Alzheimer's disease and related disorders
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
in Memento-VASCOD
Intervention Description
Pulse wave velocity assessment Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement Neuropsychological testing and behaviorial and mood scales Urinary albumin excretion measurement
Primary Outcome Measure Information:
Title
Change in cognitive performances over
Time Frame
36 months from baseline
Secondary Outcome Measure Information:
Title
Progression to clinical dementia of Alzheimer's type according to standardized criteria
Description
standardized criteria : Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and National Institute of Neurological and Communicative Disorders and Stroke Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) classifications
Time Frame
36 months from baseline
Title
Change in CSF and blood amyloid biomarkers of AD
Time Frame
24 months from baseline
Title
Change in brain atrophy and hippocampal volumes
Time Frame
24 months from baseline
Title
Progression of small vessels disease markers (white matter lesions, lacunar infarcts, microbleeds)
Time Frame
24 months from baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants to MEMENTO-Vascod should be included in MEMENTO. To have signed a specific MEMENTO-Vascod informed consent form, prior to any Vascod ancillary study related procedures To be aged 50 years old and above To have a Clinical Dementia Rating scale <0.5 and to be not demented; Exclusion Criteria: Are under guardianship Live in skilled nursing facility Are Pregnant or breast feeding women Meet brain MRI exclusion criteria (Same criteria as in Memento main protocol)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Genevieve CHENE, Prof
Organizational Affiliation
CIC-EC1401 - ISPED - CHU de Bodeaux
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Geneviève CHENE, Prof
Organizational Affiliation
CIC-EC1401 - ISPED - CHU de Bordeaux
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Carole DUFOUIL, Director
Organizational Affiliation
CIC-EC1401 - ISPED - CHU de Bordeaux
Official's Role
Study Director
Facility Information:
Facility Name
CHU d'Amiens
City
Amiens
Country
France
Facility Name
CHU de Bordeaux - Pellegrin
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Facility Name
CHU de Dijon
City
Dijon
Country
France
Facility Name
CHU de Lille
City
Lille
Country
France
Facility Name
Hospices civils de Lyon
City
Lyon
Country
France
Facility Name
AP-HM
City
Marseille
Country
France
Facility Name
CHU de Montpellier
City
Montpellier
Country
France
Facility Name
AP-HP - Hôpital BROCA
City
Paris
Country
France
Facility Name
AP-HP - Hôpital LARIBOISIERE
City
Paris
Country
France
Facility Name
CHU de Strasbourg
City
Strasbourg
Country
France

12. IPD Sharing Statement

Learn more about this trial

MEMENTO-VAScular COmponents of Dementia

We'll reach out to this number within 24 hrs